Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
11 current organization shown on this profile
Board positions
Not establishedNo board position is currently listed on this profile
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Thomas Leggett has served as Chief Financial Officer since April 2024, having previously served as CFO at Affinia Therapeutics, Black Diamond Therapeutics, and Axcella Health. He also held roles at UBS Securities, Lazard Frères, and J.P. Morgan Securities, and holds an MBA from the Wharton School.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Connections

Explore the roles, education and affiliations published in this record.

Stoke Therapeutics, Inc.

Open Stoke Therapeutics, Inc. profile →

Chief Financial Officer at Stoke Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-26

Stoke Therapeutics…Stoke Therapeutics, Inc.Thomas E. Leggett

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingSTOK DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Other Company Role, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:thomas-e-leggett
Record version
public-0

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. STOK DEF 14A executive officers

    sec filing · Source published: Apr 22, 2026 · Retrieved: May 5, 2026

    Supports 6 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Executive company: Executive at Stoke Therapeutics, Inc. · Claim reviewed: May 5, 2026
    • Executive title: Executive title: Chief Financial Officer · Claim reviewed: May 5, 2026
    • Other Company Role: Thomas E. Leggett is also linked to Clover Biopharmaceuticals as Member of the board of directors and chairman of the audit committee. · Claim reviewed: May 5, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 5, 2026

  2. Open source

    sec def 14a · Source published: Apr 22, 2026 · Retrieved: Sep 13, 2026

    Supports 1 claim
    • Professional Role: Chief Financial Officer at Stoke Therapeutics, Inc. · Claim reviewed: Sep 13, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive company · Source reportedExecutive at Stoke Therapeutics, Inc.1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Executive title · Source reportedExecutive title: Chief Financial Officer1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Other Company Role · Source reportedThomas E. Leggett is also linked to Clover Biopharmaceuticals as Member of the board of directors and chairman of the audit committee.1 source
Verification
Source reported
Confidence
70%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 5, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

View all sources2 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 5, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Other Company Role · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1623526/000119312526170362/d941184ddef14a.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 13, 2026

    Supports: Chief Financial Officer at Stoke Therapeutics, Inc. (NASDAQ: STOK)